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Prevalence of SARS-CoV antibody in all 
Hong Kong patient contacts
Key Message
The near absence of transmission 
(seroprevalence=0.19%) resulting 
in asymptomatic infection in this 
representative high-risk group of 
close contacts indicates that the 
prevailing SARS-CoV strains in 
Hong Kong almost always led to 
clinically apparent disease.
Hong Kong Med J 2009;15(Suppl 9):S27-9
Introduction
Since the SARS outbreak, considerable progress has been made in understanding 
the biology, pathogenesis, and epidemiological features of both the coronavirus 
and the disease. Epidemiological studies of hospitalised patients suggest that the 
overall transmissibility of SARS (as indicated by the basic reproductive number 
R0=2.7; 95% confidence interval [CI], 2.2-3.7) is relatively low compared with 
other pathogens.1 However, such studies could not take into account possible 
episodes of mild or moderate illness that did not resort to inpatient care and 
could not address whether asymptomatic community spread played a role in 
the 2003 epidemic. If this type of spread occurred, sufficient herd immunity 
against SARS-CoV to protect against another large-scale outbreak might have 
developed in the population. The full spectrum of disease associated with SARS-
CoV infection should be examined to define more precisely what constitutes 
a case requiring quarantine and isolation to minimise potential human-to-
human spread. Understanding these issues requires the systematic study of the 
seroprevalence of SARS-CoV antibody in a large sample stratified by age and 
other baseline characteristics, especially since children were disproportionately 
less affected by SARS, both in terms of reduced incidence and severity of 
infection. Serological surveys can be based on a random sample from the total 
population with appropriate stratification, on serum collected for other reasons 
(eg blood donors, all hospital admissions), or on surveys of persons who resided 
in sites of superspreading events or who have had close contact with a confirmed 
SARS patient.
 We report a serological survey for immunoglobulin G (IgG) against SARS-
CoV in a representative sample of close contacts of all SARS patients in Hong 
Kong (>76% had laboratory confirmation of SARS by either paired serology or 
repeat reverse transcription–polymerase chain reaction [RT-PCR] according to 
World Health Organization [WHO] criteria).2
Aims/objectives
To estimate the seroprevalence and associated predictors of SARS-CoV IgG 
antibody among all close contacts of the case cohort during the Hong Kong 2003 
outbreak.
Methods
During the epidemic (from 15 February to 22 June 2003), close contacts were 
prospectively identified by the Department of Health through standardised 
telephone interviews with all 1755 confirmed SARS patients within 1 week 
of hospital admission. A close contact was defined as a person who had cared 
for, lived with (in the same household), or came into direct contact with body 
fluids of the SARS patients within 10 days before hospital admission. A total 
of 3612 close contacts were recorded; 505 were diagnosed as having SARS. Of 
the remaining 3107 contacts, 2805 (90%) had a telephone number available, as 
provided by the primary patient. We successfully contacted 2337 (83%) of the 
contacts from 23 October to 30 November 2003, and 1776 (57% of those eligible) 
consented to a telephone interview after the purpose of the study was explained 
to them by trained public health nurses. The interview consisted of questions that 
assessed the relationship between the patients and contacts; the timing, intensity 
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and frequency of contact; precautionary measures adopted 
during contact with the patient; known contact with other 
SARS patients; clinical symptoms of febrile, respiratory, 
gastrointestinal, or constitutional illness since February 
2003; medical and travel history; and sociodemographics. 
Participants were then invited to provide blood samples 
for serological testing. Shopping coupons (worth US $25) 
were given to participants after blood was collected as 
compensation for time and travel costs.
 Samples were screened by the Government Virus 
Unit of the Department of Health by using viral lysate 
enzyme-linked immunosorbent assay (ELISA; GBI 
Biotech, Beijing). Positive results were confirmed with 
immunofluorescence assay (IFA) and neutralisation tests. 
For the IFA, microscope slides coated with SARS-CoV–
infected FRhK4 cells were incubated with serum samples 
at serial two-fold dilutions starting from 1:25. A positive 
test was indicated by cytoplasmic fluorescence under 
ultraviolet microscopy. Using IFA as the standard, the 
ELISA detects antibody with IFA titre of >25 (ie sensitivity 
of 100%) and has a specificity of 95%. Neutralisation tests 
were performed by standard virological methods with Vero 
E6 cells and SARS-CoV isolate 6109. A titre of >10 was 
considered positive. The reported sensitivity of 100% was 
for convalescent-phase serum samples taken a few weeks 
after the onset of infection in SARS patients, which should 
apply to our study. During the early phase of infection, IgM 
predominates; the ELISA kit we used detects IgG only. 
Therefore, the sensitivity was 80 to 90% (depending on the 
number of days after illness onset when the serum samples 
were taken). However, this sensitivity should not have 
affected our findings, which were based on tests carried out 
at least 6 months after the last reported case of SARS in 
Hong Kong.
Results
Of the 1068 samples analysed, two (0.19%; 95% CI, 0.02-
0.67%) contacts had a positive titre (1:25 to 1:50 on IFA 
compared with at least 1:100 in most recovered SARS 
cases) for SARS-CoV IgG antibody. None of the two 
contacts with a positive sample reported a chronic medical 
condition or being sick with febrile or respiratory illness 
from February to August 2003. Both seropositive contacts 
arose from two superspreading events in Hong Kong, ie 
Prince of Wales Hospital nosocomial outbreak and Amoy 
Gardens community outbreak.1,3 The former reported one 
other close contact, who was interviewed but declined 
to be tested. The latter was separately identified by three 
intrafamilial index patients, all of whom lived in the same 
household and reported only each other as close contacts. 
The participants who consented to testing were broadly 
similar to those who declined, except that the former group 
had relatively fewer children and comprised fewer men. 
However, those who consented to testing were more likely 
to report more frequent contact and closer relationships with 
SARS patients, more febrile or respiratory illness episodes 
since February 2003, and a travel history to SARS-affected 
regions, which may have biased our seroprevalence estimate 
upwards.
Discussion
The extent of seropositivity in close contacts of confirmed 
patients should provide the upper limit of SARS-CoV 
antibody seroprevalence in the general population, given 
the relatively intense exposure of these persons to SARS 
patients. Our finding of the near absence of transmission 
resulting in asymptomatic infection in this representative 
high-risk group of close contacts indicates that the 
prevailing SARS-CoV strains in Hong Kong almost always 
led to clinically apparent disease. Whereas some SARS 
patients (especially health care workers) might have been 
promptly admitted to hospitals, so that transmission to 
family members was reduced. Almost all SARS patients 
(perhaps with very few exceptions in children) had severe 
disease resorting to inpatient treatment; thus, infection with 
SARS-CoV almost always caused severe disease requiring 
hospitalisation.4
 Although our results suggested that SARS-CoV was 
a new virus in humans without a close precursor or an 
antigenically related virus that would have induced at least 
a small degree of cross-reactivity on serological testing, 
a recent study on a select group of 938 healthy Hong 
Kong adults (whose serum had been stored as part of a 
hepatitis B serosurvey in 2001) indicated that 1.8% of the 
sample had acquired a SARS-CoV–related virus infection 
at least 2 years before the 2003 SARS outbreak.5 The 
investigators speculated that the virus that affected these 
healthy, seropositive persons was antigenically closer to 
the recently isolated animal SARS-CoV–like virus than 
human SARS-CoV, but interspecies transmission from 
animals to humans was likely to be inefficient, as the virus 
might not have adapted in the new host.3 This hypothesis 
may explain why only a few persons became infected but 
were asymptomatic. This hypothesis would be compatible 
with the presumed asymptomatic infection observed in 
Guangdong animal traders, especially in those who handled 
masked palm civets, who had a seropositivity rate of 72.7% 
(95% CI, 49.8-89.3%) in the absence of prior overt clinical 
disease.6
 The limitations of the study included incomplete contact 
tracing (especially in the earlier parts of the epidemic) and 
potential recall bias (under-reporting of contacts by some 
patients who were too sick to answer questions). Another 
possible shortcoming was the lack of a survey of close 
contacts whose telephone numbers were not provided, 
although there was no reason to suspect they had a 
systematically different serological profile. In fact, these 
were mostly non-household contacts who would have had 
less intense exposure to SARS patients. In addition, because 
peak infectivity, as indicated by viral load, usually occurred 
during week 2 of illness, when most of the patients would 
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have been isolated in hospital (the mean symptom onset-to-
admission interval decreased from a maximum of 9.3 days 
in late February to 1.0 day by mid-May). Transmission 
to close contacts in the later stages of the epidemic was 
therefore less likely.7,8 Finally, contacts who refused to 
participate (n=561) or undergo serological testing (n=708) 
might have been due to their concerns about having SARS 
(possibly because of having SARS-like symptoms) and did 
not want to be identified and stigmatised as having been 
infected with SARS-CoV. Surveys in other countries with 
large-scale outbreaks such as Canada, China, Singapore, 
and Taiwan should be undertaken to confirm our findings.
Conclusions
The near absence of transmission resulting in 
asymptomatic infection in this representative high-risk 
group of close contacts indicates that the prevailing 
SARS-CoV strains in Hong Kong almost always led to 
clinically apparent disease. It is inferred that infection 
with SARS-CoV almost always caused severe enough 
disease requiring hospitalisation.
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